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INTRODUCTION
L -DOPA (L -3,4 -dihydroxyphenylalanine) is a
widely used drug for the treatment of Parkinson’s
disease (PD) (1, 2). Many studies showed that some
doses of L-DOPA caused hypertensive response in
human and laboratory animals. Early study reported
that injection of L-DOPA could cause the cat renal
hypertension (3), and that conscious rats orally ad-
ministered L-DOPA following parenteral admini-
stration (4) and intraperitoneal administration of L-
DOPA showed hypertensive responses (5). Intrave-
nous L-DOPA evoked some tachycardia (2) and
larger rises in blood pressure in human (6). How-
ever, these studies did not show precise mechanism
of L-DOPA-induced hypertensive response. It has
been known that tension in aortic vascular smooth
muscle induced by either α -adrenergic agonists or
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passive external stretch is related to NO release
from the endothelium (7 -9), On the other hand,
phenylephrine induces NO release by α2 receptor in
endothelium cells (10), in addition to direct contrac-
tion effect on smooth muscle. These NO-releasing
systems of the vasculature is considered to function
as a kind of self-protecting mechanism against ex-
cessive force generation by vascular smooth muscle
cells (7). However, whether hypertensive effect of
L-DOPA is related with NO signaling pathway is un-
known. In this study, we investigated the mecha-
nism of effect of L -DOPA on phenylephrine - in-
duced contractile force of blood vessels in vitro by
using several pharmacological blockers The results
indicate that the effect of L-DOPA on contractile
force of blood vessels was mediated by NO signaling
pathway via production of reactive oxygen species.
METHODS
Agents
Phenylephrine(phe), acetylcholine(Ach), sodium
nitroprusside (SNP), S-nitroso-N-acetyl - penicil-
lamine (SNAP), L-3,4-dihydroxyphenylalanine(L-
DOPA), Nω -Nitro-L-arginine (L-NNA), 8-(4 -chlo-
rophenylthio) guanosine 3’ 5’ - cyclic monophos-
phate (cpt-cGMP) , 3-(5’ -hydroxymethyl-2’ -furyl)-
1-benzyl indazole (YC-1), superoxide dismutase
(SOD) and indomethacin were purchased from
Sigma (St. Louis, MO, USA).
Preparation of aortic rings and tension measure-
ment
All animal procedures were in accordance with
the institutional guidelines for the care and use of
laboratory animals of Tokushima University. Male
Wistar rats (Japan SLC, Shizuoka, Japan) weighing
150-250 g were anesthetized by an intraperitoneal
injection of pentobarbital. The thoracic aortas were
dissected free of connective tissue and cut into ring
segments, 3- to 4- mm in length. In some experi-
ments, the aortic endothelium was removed by in-
serting a cotton thread into the lumen followed by
gentle rubbing. Each ring was then placed in a 3 ml
organ bath (Micro Easy Magnus, Kishimoto Medi-
cal ; Kyoto, Japan) and mounted on two stainless
steel wires, one of which was fastened to the bath
and the other connected to a force transducer for
the measurement of isometric tension. The bath was
filled with Krebs-Ringer bicarbonate buffer (KRB)
solution at 37and bubbled with a mixture of 95%
O2-5% CO2. The KRB contained (in mmol/L) 118
NaCl, 4.6 KCl, 2.5 CaCl2, 24.8 NaHCO3, 1.2 MgSO4,
1.2 KH2PO4, and 5.6 glucose. The ring was equili-
brated for 60 mins under a resting tension of 1.5 g
and the solution was changed at 30 min intervals.
The presence or absence of endothelium was con-
firmed by the addition of the endothelium-depend-
ent vasodilator, acetylcholine (10-6 M), after contrac-
tions had been induced by phenylephrine (α1-adren-
ergic receptor agonist) (10-6 M). Following washout
of phenylephrine and acetylcholine with KRB, the
aortic rings were contracted by adding a solution to
the bath with a high K+ concentration (50 mM KCl).
After recording the contractile force of each ring in
response to high K+, the KCl was washed out with
KRB. Each ring was then allowed to equilibrate at a
resting tension of 1.5 g for 20 min. The contractile
response in the test experiments described below
was expressed relative to that measured for the KCl-
induced contraction (1st KCl) (11, 12).
Preparation of rat smooth muscle cells
Isolation of vascular smooth muscle cells from
rats was conducted as described previously (13).
Briefly, male Wistar rats aged 8 to 10 weeks were
anesthetized with ether, and 1.0 U/g heparin was
injected into the peritoneal cavity 30 min before
surgery. Aortas were dissected and longitudinally
opened in the longitudinal direction, and endothe-
lium and adventitia were removed. The tissue was
then minced into small pieces in normal Tyrode’s
solution. The pieces were then explanted on glass
coverslips in tissue culture dishes filled with me-
dium 199 (Nissui Chemicals, Tokyo, Japan), sup-
plemented with 10% fetal bovine serum (GIBCO,
Grand Island, NY), 100 μg/ml streptomycin, and
100 μg/ml penicillin and stored in a carbon dioxide
incubator (5% CO2, 37). Single smooth muscle
cells migrated out of the tissues and adhered to the
coverslips within a few days. After culturing for 6-10
days, they were used in the experiments described
below.
Effect of L-DOPA on aortic ring contraction
Test experiments involving L-DOPA were con-
ducted on aortic rings in which contraction was in-
duced by either phenylephrine (10-9 -10-4.5 M) or KCl
(30, 50, or 80 mM). L-DOPA (10-7 to 10-4.5 M) was
added to the incubation system either 20 min prior
to or during the contraction induced by each con-
strictor. Vehicle (water)-treated rings were used as
controls.
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NO synthesis Inhibitor treatment of aortic rings
In some experiments, endothelium-derived nitric
oxide (NO) or prostaglandins were blocked by in-
cubating aortic rings with L-NNA (310-5 M) or in-
domethacin (10-5 M) to inhibit NO or prostaglandin
synthesis, respectively. The aortic rings were pre-
treated with each inhibitor for 20 min and then con-
traction was induced by phenylephrine or KCl. Each
inhibitor was present in the incubation system dur-
ing contraction.
Determination of L-DOPA-inhibited endothelium-
dependent aortic relaxation
In the experiment of effect of SNP, cpt-cGMP or
acetylcholine, SNP (NO donor ; 10-11 -10-6 M) or cpt-
cGMP (10-9-10-4 M) were added to the bath during
the contraction induced by phenylephrine (10-5 M)
or KCl (50 mM). In other experiments, acetyl-
choline (10-6 M)-induced vasorelaxation was as-
sessed in aortic rings that had been contracted by
phenylephrine (10-5 M).
Effect of YC-1 on L-DOPA-inhibited relaxation of
aortic rings
Aortic rings without endothelium pretreated with
L-DOPA (10-5 M) for 20 mins and then induced con-
traction by phenylephrine (10-5 M). YC-1(0.1-100
uM) per 10 mins added into the bath with the subse-
quent contraction by phenylephrine. Vehicle (water)-
treated rings were used as controls.
Effect of SOD on L-DOPA-inhibited endothelium-
dependent relaxation of aortic rings
Aortic rings with endothelium were pretreated
with SOD (150 U/ml) for 20 mins and then induced
contraction by phenylephrine (10-5 M). L-DOPA
(10-7-10-4.5 M) were added to the bath after induced
contraction. Vehicle (water)-treated rings were used
as controls.
Measurement of intracellular cGMP
The rat smooth muscle cells cultured in a 35 mm
dish were treated with or without L-DOPA (10-5 M)
in the Krebs-Ringer Hepes buffer solution (contain-
ing 125 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 2.6
mMMgSO4, and 5 mM Hepes, pH 7.4) for 5 min at
37. Cells were then stimulated with SNAP (1, 10,
or 100 M) for 5 mins. Following washing two times
with ice-cold phosphate-buffered saline, intracel-
lular cGMP was extracted with 1 ml of HCl (0.1 M)
under shaking for 20 minutes at room temperature.
The extracted solution was centrifuged at 80g for
5 minutes. The concentration of cGMP in the super-
natant was measured with a cGMP EIA kit (Cayman
Chemical, Michigan, USA) according to the manu-
facturer’s protocol. The concentration of intracellu-
lar cGMP was expressed as pmol per mg protein.
Statistical analysis
Data are expressed as the meanS.D. and were
analyzed by ANOVA plus Bonferroni multiple com-
parison tests. A P -value0.05 was regarded as sta-
tistically significant.
RESULTS
L-DOPA potentiated phenylephrine-induced con-
traction through endothelium- and NO-dependent
pathways
Firstly, we examined the effect of L-DOPA on
vascular contraction using rat aortic rings precon-
tracted by phenylephrine (Fig. 1-a). Fig. 1-b showed
a trace demonstrating the effect of L-DOPA on rat
aortic rings pretreated with phenylephrine. As shown
in Fig. 1-c, administration of L-DOPA alone to the
rings without phenylephrine (vehicle group) did not
induce contraction. However, when the rings were
precontracted by phenylephrine, subsequent admini-
stration of L-DOPA potentiated contraction in a
dose-dependent manner. After washed with KRB,
the contractile effect of the rings caused by L-DOPA
disappeared and L-DOPA retreatment restored rat
aortic ring contraction to phenylephrine precontrac-
tion state. This effect of L-DOPA was not affected
by pretreatment of the rings with indomethacin
(10-5 M), an inhibitor of prostaglandin synthesis
(Fig. 1-c). In contrast, pretreatment of the rings
with L-NNA (310-5 M), an inhibitor of NO synthe-
sis, or the removal of endothelium from the rings
(Fig. 1-d) significantly inhibited the L-DOPA -me-
diated increase in contractile force. Dopamine and
its metabolite, DOPAC (L-3,4 - dihydroxyphenylace-
tic - acid), failed to enhance the phenylephrine-in-
duced aortic contraction when these substances
were used at concentrations up to 10-5 M (data not
shown).
To examine the effect of L-DOPA pretreatment
on subsequent phenylephrine-induced contraction,
L-DOPA (10-5 M) was administrated 20 min prior to
phenylephrine (10-9 -10-4.5 M) (Fig. 2-a). As shown in
Fig. 2-b, L-DOPA pretreatment potentiated the sub-
sequent phenylephrine-induced contraction in rings
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Fig. 1 L-DOPA potentiated phenylephrine- induced contraction of rat aortic rings through endothelium- and NO- dependent path-
ways (I). (a) Experimental design. L-DOPA (10-7 -10-4.5 M) was administrated cumulatively to enthothelium-intact/-denuded aortic rings
which had been pretreated with or without (vehicle) phenylephrine (10-5 M). In some groups, L-NNA (310-5 M) and/or indometh-
acin (Indo ; 10-5 M) were administrated to the aortic rings 20 min prior to phenylephrine (or vehicle) administration (inverted trian-
gle). (b) Trace demonstrating the effect of L-DOPA on enthothelium-intact rat aortic rings pretreated with phenylephrine. (c) Con-
centration -response curves for L-DOPA-induced change in the contractile force of endothelium-intact aortic rings. (d) Concentra-
tion -response curves for L-DOPA-induced change in the contractile force of endothelium-denuded aortic rings. Data are expressed
as meansS.D. for 4 aortic rings in each group. * p0.05 compared with vehicle group (open circles). p0.05 compared with Phen-
ylephrine group (closed circles).
a
b c d
Fig. 2 L-DOPA potentiated phenylephrine- induced contraction of rat aortic rings through endothelium- and NO- dependent path-
ways (II). (a) Experimental design. Phenylephrine (Phe : 10-9 -10-4.5 M) was administrated cumulatively to endothelium-intact/denuded
rat aortic rings which had been pretreated with or without (vehicle) L-DOPA (10-5 M). In some groups (panel c), L-NNA (310-5
M) was administrated to the aortic rings together with L-DOPA (or vehicle) (inverted triangle). (b) Concentration-response curves
for phenylephrine- induced changes in contractile force of endothelium-intact (E+) aortic rings. (c) Concentration-response curves
for phenylephrine- induced change in contractile force of endothelium-intact (E+) aortic rings pretreated with L-NNA. (d)
Concentration-response curves for phenylephrine- induced changes in contractile force of endothelium-denuded (E-) aortic rings.
There are no difference between experimental group and control in (c) and (d). Data are expressed as meansS.D. for 4 aortic
rings in each group. * p0.05 compared with vehicle group (open circles).
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with intact endothelium. It is well known that the
blockade of endothelium-derived NO or removal
of endothelium itself induces hypercontractility of
blood vessels (11). L-DOPA pretreatment did not
further increase contractile force in these NO-
blocked and endothelium-denuded aortic rings (Fig.
2c and d). These results suggest that L-DOPA po-
tentiated phenylephrine-induced aortic contraction
through endothelium- and NO- dependent path-
ways.
We also examined the effect of L-DOPA on depo-
larization-induced contraction of rat aortic rings pre-
contracted by KCl (50 mM). Administration of L-
DOPA during KCl-induced contraction increased
contractile force in a dose-dependent manner. This
effect of L-DOPA was almost completely inhibited
by pretreatment of the rings with L-NNA (310-5
M) as well as in the rings without endothelium (data
not shown).
L-DOPA inhibited endothelium-dependent relaxa-
tion of the aorta
Next, we tested whether potentiation of L-DOPA
is due to inhibition of endothelium-dependent re-
laxation by NO signal. The effect of L-DOPA on
endothelium-dependent vasorelaxation was exam-
ined using aortic rings which had been precon-
tracted by phenylephrine (Fig. 3-a). As shown in
Fig. 3-b, acetylcholine (10-6 M) almost completely
relaxed the tension in aortic ring with intact endo-
thelium.
Since acetylcholine - induced vasorelaxation
depends largely on endothelium-derived NO in con-
duit arteries (14), this relaxation was inhibited by
pretreatment with L-NNA (Fig. 3-c). L-DOPA pre-
treatment also inhibited acetylcholine-induced va-
sorelaxation to the same extent as that observed in
the L-NNA-treated rings (Fig. 3-c).
L-DOPA inhibited exogenous NO-dependent but
not cGMP-mediated vasorelaxation
NO activates guanylate cyclase which in turn in-
creases the concentration of intracellular cGMP in
the smooth muscle cells (15). The rise of cGMP
levels triggers subsequent vasorelaxation (15). To
further study the mechanism of L-DOPA, we tested
the effect of L-DOPA on cGMP induced vasorelaxa-
tion using the membrane-permeable cGMP analog,
cpt-cGMP. Endothelium-denuded aortic rings were
first precontracted by phenylephrine or KCl (Fig.
a
b c
Fig. 3 L-DOPA inhibited acetylcholine- induced vasorelaxation in rat aortic rings. (a) Experimental design. Acetylcholine (ACh)
(10-6 M) was administrated to endothelium-intact aortic rings that had been precontracted by phenylephrine (Phe ; 10-5 M). L-DOPA (10-5
M), L-NNA (310-5 M) or vehicle was administrated to the endothelium-intact aortic rings 20 min prior to phenylephrine admini-
stration. (b) Acetylcholine concentration induced maximum relaxation in endothelium-intact ring. Data are expressed as meansS.
D. for 4 aortic rings in each group. * p0.05 compared with vehicle group. (c) Acetylcholine- induced maximum relaxation in each
endothelium-intact ring.
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4 - a), and after the contraction reached a steady
level, subsequent relaxing responses induced by
cpt-cGMP (10-9-10-4 M) were assessed in the pres-
ence or absence of L-DOPA (10-5 M). L-DOPA pre-
treatment failed to affect cpt-cGMP-mediated va-
sorelaxation in the rings contracted with phen-
ylephrine (Fig. 4-b) or KCl- (Fig. 4-c).
L-DOPA-inhibited vasorelaxation was not soluble
guanylyl cyclase-dependent
Soluble guanylyl cyclase (sGC) expressed by en-
dothelium of blood vessel is considered the key en-
zyme mediating vascular relaxation induced by NO.
By the formation of cyclic GMP, this enzyme me-
diates NO-mediated vascular smooth muscle relaxa-
tion (16, 17). In order to probe whether L-DOPA-
inhibited vasorelaxation was caused by blocking the
action of soluble guanylyl cyclase, effect of YC-1 (an
activator of guanylyl cyclase) (18) on the aortic ring
contraction was examined. In aortic rings without
endothelium pretreatmented with L-DOPA (10-5 M),
YC-1was added into the bath and subsequent con-
traction effect of rings by phenylephrine was stud-
ied (Fig. 5-a). YC-1 (0.1 μM-100 μM) could relax
the rings precontracted by phenylephrine in dose-
dependent manner. There was no significant dif-
ference in relaxation between the ring with and
without pretreatment by L-DOPA (Fig. 5-b), sug-
gesting that solube guanylyl cyclase is not a target
of L-DOPA-inhibited vasorelaxation. Similar effect
was observed in the experiment using atrial natriu-
retic peptide, an activator of membrane guanylyl cyc-
lases (data not shown).
L-DOPA attenuates NO-donor-induced cGMP pro-
duction in cultured rat aortic smooth muscle cells
and inhibits acetylcholine-induced relaxation
To examine whether L-DOPA affects cGMP pro-
duction by NO, cultured rat aortic smooth muscle
cells were stimulated with a donor of NO, SNAP (1-
100 μM), and intracellular cGMP levels were meas-
ured in the presence or absence of L-DOPA (10-5
a
b
c
Fig. 4 L-DOPA did not attenuated exogenous cGMP-mediated
vasorelaxation. (a) Experimental design. cpt-cGMP (10-9 -10-4 M)
was administrated cumulatively to endothelium-denuded aortic
rings that had been precontracted by phenylephrine (Phe ; 10-5
M, panel b) or KCl (50 mM, panel c). L-DOPA (10-5 M) or ve-
hicle was administrated to the aortic rings 20 min prior to phen-
ylephrine or KCl administration. (b) Concentration-response
curves for phenylephrine or (c) KCl- induced change in contractile
force of endothelium-denuded aortic rings. Data are expressed
as meansS.D. for 4 aortic rings in each group. p0.05 com-
pared with vehicle group (open circles).
a
b
Fig. 5 Effects of YC-1 on tension of rat aortic rings (a) Experi-
mental design. Aortic rings without endothelium pretreatmented
with L-DOPA (10-5 M) for 20 mins YC-1 (0.1 -100 uM) per 10
mins were added into the bath with the subsequent precontrac-
tion of rings by pheylephrine (10-5 M). Vehicle(water) - treated
rings were used as control. (b) Concentration-response curves
for YC-1- induced L-DOPA-mediated relaxation of rings without
endothelium of YC-1 treatment did not show significant differ-
ence compared with that of rings of L-DOPA no-pretreatment.
Data are expressed as meansS.D. for 4 aortic rings in each
group. P0.1
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M). As shown in Fig. 6, L-DOPA treatment inhib-
ited cGMP production at higher SNAP concentra-
tions. We also tested effect of L-DOPA of exogenous
NO on SNP-induced relaxation. The experimental
design was showed by Fig. 7-a Namely the L-DOPA-
Pretreatmented endothelium-denuded aortic rings
were precontreated by phenylephrine or KCl and
then added SNP (NO doner) to observe L-DOPA
attenuated effect on exogenous NO-dependent Va-
sorelaxtion the results showed that L-DOPA pre-
treatment significantly attenuated vasorelaxation re-
sponses induced by SNP (10-11 -10-6 M) (Figs. 7-b
and 7-c).
L-DOPA mediated inhibition of relaxation is due to
inactivation of NO by oxygen free radicals
Increased production of reactive oxygen species
(ROS) reduces the effect and/or bioavailability of
NO, leading to an impaired endothelial function.
Through auto-oxidation, L-DOPA forms reactive
free radicals such as hydroxyl radicals, oxygen free
radicals. Oxygen free radicals (O2 -) can decrease
ring relaxation by inactivation of NO (19, 20). In this
experiment we used SOD to decrease O2 - genera-
tion in order to further confirm NO effect in L-
DOPA -mediated contraction. Aortic rings with en-
dothelium were pretreated with SOD (150 u/ml)
for 20 mins. L-DOPA (10-7-10-4.5 M) were added to
the bath with the subsequent contraction by phen-
ylephrine (10-5 M) (Fig. 8-a). Fig. 8-b showed that
SOD (150 U/ml) pretreatment inhibited contraction
by L-DOPA of rings with endothelium.
DISCUSSION
Our present studies indicated that L -DOPA
Fig. 6 L-DOPA attenuated NO-donor- induced cGMP produc-
tion in cultured rat aortic smooth muscle cells. Cells were treated
with or without (vehicle) L-DOPA (10-5 M) for 5 min and then
stimulated with SNAP (1, 10, or 100 μM) for 5 min. After wash-
ing two times with ice-cold phosphate-buffered saline, intracel-
lular cGMP was extracted and quantified as described in “Mate-
rials and Methods” section. Data are expressed as meansS.D.
for 4 culture dishes (35 mm dishes) in each group. * p0.05
compared with vehicle group.
a
b c
Fig. 7 L-DOPA attenuated exogenous NO-dependent vasore-
laxation. (a) Experimental design. SNP (10-11 -10-6 M) was ad-
ministrated cumulatively to endothelium-denuded aortic rings
that had been precontracted by phenylephrine (10-5 M) or KCl
(50 mM). L-DOPA (10-5 M) or vehicle was administrated to the
aortic rings 20 min prior to phenylephrine or KCl administration.
(b) Concentration-response curves for phenylephrine or (c)
KCl- induced change in contractile force of endothelium-denuded
aortic rings. Data are expressed as meansS.D. for 4 aortic rings
in each group. * p0.05 compared with vehicle group (open cir-
cles).
a
b
Fig. 8 Effect of SOD on L-DOPA-mediated contraction of
aortic rings. (a) Experimental design. Aortic rings with endo-
thelium were pretreated with SOD (150 u/ml) for 20 mins. L-
DOPA (10-7 -10-4.5 M) were added to the bath with the subsequent
contraction by phenylephrine (10-5 M). Vehicle (water) - treated
rings were used as controls. (b) Contractile response of endo-
thelium- intact aortic rings pretreated by SOD in the condition of
various L-DOPA concentration. Data are expressed as means
S.D. for 4 aortic rings in each group, * p0.01.
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increased the α -adrenergic receptor-mediated and
depolarization-induced vascular contraction and de-
creased ACh-induced vascular relaxation in endo-
thelium-intact rat aorta, which was inhibited by L-
NNA pretreatment. L-DOPA attenuated the rise in
the intracellular cGMP and inhibited vasorelaxation
with an NO donor, but not those with cpt-cGMP, a
membrane-permeable cGMP analog, or YC-1, an
activator of guanylyl cyclase, suggesting that action
of L-DOPA might be upstream of guanylyl cyclase.
SOD (150 U/ml) pretreatment inhibited contraction
by L-DOPA of rings with endothelium, suggesting
that production of reactive oxygen species by L-
DOPA decreases the NO action. All these data dem-
onstrated that the underlying mechanism of vaso-
contractive effect of L-DOPA was inhibition of NO-
dependent vasorelaxation via production of reactive
oxygen species from L-DOPA.
It is well know that nitric oxide (NO) is the major
mediator of endothelium-dependent relaxation in
aorta (15, 21, 22), which is formed from the conver-
sion of L-arginine by nitric oxide synthase (NOS) in
endothelium cell and released. This endothelium -de-
rived NO stimulates the activity of soluble guanylate
cyclase (sGC) in smooth muscle cells, leading to an
increase in cyclic guanosine-3’,5’- monophosphate
(cGMP) and finally to calcium depletion from the
cytosolic space and vascular smooth muscle relaxa-
tion (15, 21-23). Various agonists such as NE (no-
radrenaline), phenylephrine, 5HT can stimulate the
release of NO from the endothelium during vasocon-
tractile response to them (9). In our present study,
we found that L-DOPA increased the phenylephrine
(α1 -adrenergic receptor)-mediated and depolariza-
tion-induced vascular contraction in endothelium-
intact rat aorta, which was inhibited by L-NNA pre-
treatment, suggesting this reaction is mediated by
NO pathway. Meanwhile, we also found that L-
DOPA pretreatment inhibited acetylcholine-induced
vasorelaxation. The acetylcholine-induced vasore-
laxation is largely mediated by endothelium-derived
NO in conduit arteris (9). Effect of NO is mainly me-
diated by production of cGMP. Thus, we studied the
effect of L-DOPA on cGMP. L-DOPA could not re-
duced relaxation by cGMP, such as membrane per-
meable cGMP (cpt-cGMP), or soluble guanylate
cyclase activator (YC-1), suggesting that the intra-
cellular signaling pathway downstream from cGMP
would not contribute this mechanism. Nakatsubo et
al. also found that L-DOPA decreased fluorescence
levels of diaminofluorescein-2 (DAF-2), a widely
used indicator of NO (24). In our preliminary study,
L-DOPA decreased nitroprusside-induced fluores-
cence levels of DAF-2 in the presence of an NO do-
nor in cell-free system (data not shown). This hy-
pothesis is also supported by our data that SOD
pretreatment of rings with endothelium induced the
subsequent ring relaxation.
L-DOPA is molecularly unstable and can rapidly
auto-oxidize in the presence of oxygen or light and
oxidize enzymatically to yield free radicals : semiqui-
nones, O-quinone derivatives and several free radi-
cals such as hydrogen peroxide (H2O2 -) and super-
oxide (O2 -). Rocchitta et al. (25) reported that auto-
oxidation of exogenous L-DOPA occurs in vivo in
the extracellular compartment of the freely moving
rat with a consequent formation of L-DOPA semiqui-
none (L-DOPA-SQ) in dialysates. NO reacting with
superoxide generates peroxynitrite (O=NOO-) to
block NO signaling pathway by inactivating NO (20,
26, 27), leading to decrease of ring relaxation (12,
13). L-DOPA is transported into mammalian cells
through the L-type amino acid transporter 1 (LAT1)
(13), which is also expressed in vascular endothe-
lium (28). In vitro experiments showed that L-DOPA
can lead to accumulation of O2 -, and the addition of
SOD resulted in higher levels of NO2 - (27). In vivo
experiment also revealed that SOD can completely
inhibit L-DOPA auto-oxidation (20) and decrease
spontaneous tone in endothelium-intact rings by
scavenging O2 - and thereby freeing endothelium-
derived NO to relax the blood vessel (29). There-
fore, we concluded that L-DOPA mediated inhibi-
tion of relaxation is due to inactivation of NO by oxy-
gen free radicals. We do not know whether L-DOPA
could produce vasoconstriction via production of re-
active oxygen species in vivo , because in vivo endo-
genous antioxidants, such as ascorbic acid or Vita-
min E. Further investigation is needed to clarify in
vivo effect of L-DOPA.
MAO-A/B mixed inhibitors may be efficacious in
the inhibition of dopamine metabolism and the treat-
ment of PD (30, 32), but there are some side effects
of increasing the blood pressure in the presence of
a non-selective monoamine oxidase (MAO)-A/B in-
hibitor or a selective MAO-A inhibitor, L-DOPA in-
creased blood pressure in both PD patients and rats
(4, 33). These results indicate that L-DOPA exerts
directly on its vasoconstrictive effect without conver-
sion to dopamine.
Minimizing the side effects of hypertension by L-
DOPA treatment would be necessary for the main-
tenance of physical as well as mental well-being of
PD patients. The NO-inhibiting effect of L-DOPA on
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the vasculature could be applicable to the establish-
ment of a novel therapeutic strategy for the treat-
ment of cardiovascular disorders in PD patients. The
concentration of L-DOPA used in the present study
(mainly 10-5 M) is near the plasma concentration in
L-DOPA-treated PD patients (approximately 0.5-
1.010-5 M) (34). Thus, L-DOPA at this concentra-
tion is considered to be enough to inhibit the NO
pathway in these patients. From our study, however,
in the absence of vasoconstrictors, L-DOPA did not
induce contraction of rat aortic rings and the effect
of L-DOPA on blood pressure in PD patients was
also complex. L-DOPA-mediated inhibition of the
NO pathway would result in vasoconstriction when
endothelial production of NO was high. However,
vasoconstriction due to NO inhibition might be
offset by an L-DOPA-mediated sympathetic inhibi-
tion. Thus, further studies are needed to clarify the
interaction of these different mechanisms on the
regulation of the cardiovascular system in PD pa-
tients treated with L-DOPA. All together, our experi-
mental results revealed the mechanism about hyper-
tensive effect of L-DOPA and provided a new pos-
sibility to the establishment of a novel therapeutic
strategy for the treatment of PD patients to avoid
side effects (e.g. hypertension) caused by therapy.
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